MXPA05010793A - Beta-carbolinas utiles para tratar enfermedades inflamatorias. - Google Patents
Beta-carbolinas utiles para tratar enfermedades inflamatorias.Info
- Publication number
- MXPA05010793A MXPA05010793A MXPA05010793A MXPA05010793A MXPA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A MX PA05010793 A MXPA05010793 A MX PA05010793A
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- inflammatory disease
- treating inflammatory
- useful
- carbolines
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46146803P | 2003-04-09 | 2003-04-09 | |
| PCT/US2004/011080 WO2004092167A1 (en) | 2003-04-09 | 2004-04-09 | Beta-carbolines useful for treating inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05010793A true MXPA05010793A (es) | 2005-12-05 |
Family
ID=33299818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05010793A MXPA05010793A (es) | 2003-04-09 | 2004-04-09 | Beta-carbolinas utiles para tratar enfermedades inflamatorias. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7727985B2 (https=) |
| EP (1) | EP1611134A1 (https=) |
| JP (1) | JP2006522824A (https=) |
| KR (1) | KR20060006031A (https=) |
| CN (1) | CN1802375A (https=) |
| AU (1) | AU2004230952A1 (https=) |
| BR (1) | BRPI0409263A (https=) |
| CA (1) | CA2521300A1 (https=) |
| CO (1) | CO5700746A2 (https=) |
| CR (1) | CR8042A (https=) |
| EA (1) | EA009121B1 (https=) |
| EC (1) | ECSP056145A (https=) |
| HR (1) | HRP20050926A2 (https=) |
| MA (1) | MA27837A1 (https=) |
| MX (1) | MXPA05010793A (https=) |
| NI (1) | NI200500174A (https=) |
| NO (1) | NO20054598L (https=) |
| OA (1) | OA13115A (https=) |
| RS (1) | RS20050832A (https=) |
| TN (1) | TNSN05257A1 (https=) |
| WO (1) | WO2004092167A1 (https=) |
| ZA (1) | ZA200508198B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
| BRPI0509660A (pt) * | 2004-04-09 | 2007-10-09 | Millennium Pharm Inc | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP5249772B2 (ja) * | 2005-11-22 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | キナーゼの阻害剤として有用な三環式化合物 |
| EP2001455A2 (en) | 2006-03-15 | 2008-12-17 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| WO2008002246A1 (en) * | 2006-06-28 | 2008-01-03 | Astrazeneca Ab | A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient. |
| EP2125841A1 (en) * | 2006-12-13 | 2009-12-02 | Gilead Sciences, Inc. | Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction |
| US20090131422A1 (en) * | 2007-10-23 | 2009-05-21 | Millennium Pharmaceuticals, Inc. | Salts of an IKK inhibitor |
| US20090137579A1 (en) * | 2007-10-23 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Mesylate salt of an IKK inhibitor |
| US20110111417A1 (en) | 2008-05-14 | 2011-05-12 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
| EP2366699B1 (en) | 2008-10-02 | 2013-08-07 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
| KR101461767B1 (ko) | 2010-03-30 | 2014-11-13 | 노파르티스 아게 | 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제 |
| CN103596949A (zh) * | 2011-03-28 | 2014-02-19 | Sjt分子研究有限公司 | 用于代谢综合征的治疗的化合物 |
| CN102416014B (zh) * | 2011-09-13 | 2012-11-21 | 河南中医学院 | 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用 |
| CN102391323B (zh) * | 2011-10-18 | 2013-09-25 | 首都医科大学 | 四氢-β-咔啉衍生物、其制备方法及其用途 |
| KR101646916B1 (ko) | 2015-07-13 | 2016-08-09 | 강원대학교산학협력단 | 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물 |
| WO2017067670A1 (en) | 2015-10-23 | 2017-04-27 | Pharmathen S.A. | A novel process for the preparation of tryptamines and derivatives thereof |
| CN109593089B (zh) * | 2019-01-24 | 2022-01-28 | 西南大学 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
| CN112824387B (zh) * | 2019-11-21 | 2023-03-21 | 济南尚博生物科技有限公司 | 一种2-甲基烟酸酯及其制备方法和应用 |
| CN117510494B (zh) * | 2023-11-07 | 2024-04-19 | 桂林医学院附属医院 | β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2242402T3 (es) * | 1998-08-12 | 2005-11-01 | Pfizer Products Inc. | Inhibidores de tace. |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| HK1054039B (zh) * | 2000-03-15 | 2010-04-16 | 萨诺费－阿文蒂斯德国有限公司 | 取代的β-咔啉 |
| EP1268477B1 (en) * | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| ATE363473T1 (de) * | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| US9248124B2 (en) * | 2001-11-07 | 2016-02-02 | Millennium Pharmaceuticals, Inc. | Use of inhibitors of IκB kinase for the treatment of cancer |
| US7396943B2 (en) * | 2003-03-07 | 2008-07-08 | Eli Lilly And Company | Opioid receptor antagonists |
| BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
-
2004
- 2004-04-09 BR BRPI0409263-5A patent/BRPI0409263A/pt not_active IP Right Cessation
- 2004-04-09 WO PCT/US2004/011080 patent/WO2004092167A1/en not_active Ceased
- 2004-04-09 CA CA002521300A patent/CA2521300A1/en not_active Abandoned
- 2004-04-09 MX MXPA05010793A patent/MXPA05010793A/es active IP Right Grant
- 2004-04-09 EA EA200501584A patent/EA009121B1/ru not_active IP Right Cessation
- 2004-04-09 JP JP2006509889A patent/JP2006522824A/ja active Pending
- 2004-04-09 OA OA1200500279A patent/OA13115A/en unknown
- 2004-04-09 CN CNA2004800160170A patent/CN1802375A/zh active Pending
- 2004-04-09 RS YUP-2005/0832A patent/RS20050832A/sr unknown
- 2004-04-09 HR HR20050926A patent/HRP20050926A2/hr not_active Application Discontinuation
- 2004-04-09 US US10/821,545 patent/US7727985B2/en not_active Expired - Lifetime
- 2004-04-09 AU AU2004230952A patent/AU2004230952A1/en not_active Abandoned
- 2004-04-09 EP EP04759390A patent/EP1611134A1/en not_active Withdrawn
- 2004-04-09 KR KR1020057019268A patent/KR20060006031A/ko not_active Ceased
-
2005
- 2005-10-06 NO NO20054598A patent/NO20054598L/no not_active Application Discontinuation
- 2005-10-07 NI NI200500174A patent/NI200500174A/es unknown
- 2005-10-07 TN TNP2005000257A patent/TNSN05257A1/en unknown
- 2005-10-11 ZA ZA200508198A patent/ZA200508198B/xx unknown
- 2005-10-12 CR CR8042A patent/CR8042A/es not_active Application Discontinuation
- 2005-11-04 CO CO05113041A patent/CO5700746A2/es not_active Application Discontinuation
- 2005-11-07 EC EC2005006145A patent/ECSP056145A/es unknown
- 2005-11-09 MA MA28592A patent/MA27837A1/fr unknown
-
2009
- 2009-12-17 US US12/640,335 patent/US20100093713A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN05257A1 (en) | 2007-07-10 |
| OA13115A (en) | 2006-11-10 |
| WO2004092167A8 (en) | 2006-01-05 |
| MA27837A1 (fr) | 2006-04-03 |
| NO20054598L (no) | 2005-10-27 |
| EA009121B1 (ru) | 2007-10-26 |
| EA200501584A1 (ru) | 2006-06-30 |
| BRPI0409263A (pt) | 2006-03-28 |
| ECSP056145A (es) | 2006-04-19 |
| AU2004230952A1 (en) | 2004-10-28 |
| CR8042A (es) | 2006-05-30 |
| EP1611134A1 (en) | 2006-01-04 |
| CO5700746A2 (es) | 2006-11-30 |
| CN1802375A (zh) | 2006-07-12 |
| JP2006522824A (ja) | 2006-10-05 |
| KR20060006031A (ko) | 2006-01-18 |
| WO2004092167A1 (en) | 2004-10-28 |
| US20040235839A1 (en) | 2004-11-25 |
| RS20050832A (sr) | 2007-12-31 |
| HRP20050926A2 (en) | 2006-06-30 |
| CA2521300A1 (en) | 2004-10-28 |
| US20100093713A1 (en) | 2010-04-15 |
| NO20054598D0 (no) | 2005-10-06 |
| NI200500174A (es) | 2006-04-17 |
| ZA200508198B (en) | 2007-01-31 |
| US7727985B2 (en) | 2010-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05257A1 (en) | Beta-carbolines useful for treating inflammatory disease | |
| IL172942A0 (en) | Pyrazoloisoquinoline derivatives as kinase inhibitors | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| NZ542616A (en) | P38 inhibitors and methods of use thereof | |
| TNSN07323A1 (en) | Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors | |
| MY142988A (en) | Novel aminobenzophenone compounds | |
| PT2332940E (pt) | Azaindoles úteis como inibidores de jak e outras proteínas quinases | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| ATE339418T1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
| SE0301700D0 (sv) | Novel compounds | |
| MXPA04002682A (es) | Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion. | |
| TW200510407A (en) | Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors | |
| TW200700422A (en) | Compounds for inhibiting ksp kinesin activity | |
| AU2002358390A1 (en) | Novel compounds | |
| TNSN06321A1 (en) | Beta-carbolines useful for treating inflammatory disease | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| TW200700066A (en) | Compounds for inhibiting ksp kinesin activity | |
| BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
| DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
| MXPA03011167A (es) | Derivados de carbolina utiles como ihibidores de pdev. | |
| UA84016C2 (ru) | Бета-карболины, полезные для лечения воспалительных заболеваний, фармацевтическая композиция на их основе | |
| WO2003080624A3 (en) | Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases | |
| MXPA04004757A (es) | Uso de una ascomicina para el tratamiento de blefaritis. | |
| SE0200119D0 (sv) | Novel compounds | |
| MXPA05006150A (es) | Derivados de 2-oxopiridin-3-il tiadiazol para usarse en el tratamiento de enfermedades relacionadas con proliferacion celular y apoptosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |